Pmgc Holdings Other 8-K Filing
PMGC Holdings and its subsidiary NorthStrive Biosciences entered into a binding payment agreement with Longevity Health Holdings to secure royalty payments from the 2025 sale of the Elevai Skincare business. The agreement converts a 5% net sales royalty into scheduled monthly cash payments through August 2031, including interest and mandatory prepayments tied to future capital events. This restructuring provides PMGC with visible, non-dilutive cash flow while allowing it to focus on its core manufacturing and defense technology segments.
- Counterparty
- Longevity Health Holdings, Inc.
- Term
- through Aug 2031